BioCentury | Jan 7, 2021
Finance
Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest
...on contributions from six prior investors including MPM Capital, its founding investor.The funds will carry Werewolf Therapeutics Inc....
...UPMC Enterprises and DC Investment Partners, as well as MPM.TARGETSIL-2 – Interleukin-2IL-12 – Interleukin-12 Paul Bonanos Werewolf Therapeutics Werewolf Therapeutics Inc....
...UPMC Enterprises and DC Investment Partners, as well as MPM.TARGETSIL-2 – Interleukin-2IL-12 – Interleukin-12 Paul Bonanos Werewolf Therapeutics Werewolf Therapeutics Inc....
